Immunohistochemical markers of proliferation and vascularisation in preneoplastic bronchial lesions and invasive non-small cell lung cancer

Neoplasma

Volumn 56, Issue 5, 2009, Pages 414-421

  Cavarga, I ^a   Kocan, P ^a   Boor, A ^a   Belak, J ^a   Zak, V ^a   Kluchova, Z ^a   Slavik, L ^a   Tkacova, R ^a  

^a L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

Author keywords

Autofluorescence bronchoscopy; Cyclooxygenase 2; Ki 67; Microvessel density; Non small cell lung cancer; PCNA protein

Indexed keywords

CD34 ANTIGEN; CYCLINE; CYCLOOXYGENASE 2; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PROTEOCHONDROITIN SULFATE; BIOLOGICAL MARKER; PTGS2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRONCHUS BIOPSY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LUNG CARCINOGENESIS; LUNG DYSPLASIA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MICROVASCULATURE; PHENOTYPE; PRECANCER; SQUAMOUS EPITHELIUM; TUMOR VASCULARIZATION; BRONCHUS TUMOR; CANCER INVASION; CHEMISTRY; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRONCHIAL NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 69849103071     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_05_414     Document Type: Article

References (36)

1. GREENLEE RT, MURRAY T, BOLDEN S et al. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33. doi:10.3322/canjclin.50.1.7 PMid:10735013
2. VAN MEERBECK JP, MORO D, SCAGLIOTTI GV et al. Bronchogenic carcinoma. In: Pulmonary diseases, Grassi C (Ed), McGraw-Hill International (UK) Ltd. 2005, pp. 325-346.
3. KENNEDY TC, MILLER Y, PRINDIVILLE S. Screening for lung cancer revisited and the role of sputum cytology and fluorescence bronchoscopy in a high-risk group. Chest 2000; 117: 72S-79S. doi:10.1378/chest.117.4-suppl-1.72S PMid:10777459
4. VOGELSTEIN B, KINZLER KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-141. doi:10.1016/0168-9525(93)90209-Z PMid:8516849
5. JEANMART M, LANTUEJOUL S, FIEVET F et al. Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. Clin Cancer Res 2003; 9: 2195-2203.
6. SHCHORS K, EVAN G. Tumor angiogenesis: cause or consequence of cancer? Cancer Res 2007; 67: 7059-7061. doi:10.1158/0008-5472.CAN-07-2053 PMid:17671171
7. YUKIO H, YOKOSE T, HIROSE Y et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 200; 30: 73-81.
8. MASCAUX C, MARTIN B, VERDEBOUT JM et al. COX- 2 expression during early lung squamous cell carcinoma oncogenesis. Eur Respir J 2005; 26: 198-203. doi:10.1183/09031936.05.00001405 PMid:16055866 (Pubitemid 41079062)
9. MEERT AP, FEOLI F, MARTIN B et al. Ki67 expression in bronchial preneoplastic lesions and carcinoma in situ defined according to the new 1999 WHO/IASLC criteria: a preliminary study. Histopathology 2004; 44: 47-53. doi:10.1111/j.1365-2559.2004.01748.x PMid:14717669
10. PUGLISI F, APRILE G, BRUCKBAUER M et al. Combined analysis of MIB-1 and thyroid transcription factor-1 predicts survival in non-small cell lung carcinomas. Cancer Lett 2001; 162: 97-103. doi:10.1016/S0304-3835(00)00625-X PMid:11121867
11. MAOUNIS NF, CHORTI M, APOSTOLAKIS E et al. Prognostic impact of deoxyribonucleic acid (DNA) image analysis cytometry and immunohistochemical expression of Ki67 in surgically resected non-small cell lung cancers. Cancer Detect Prev 2006; 30: 507-514. doi:10.1016/j.cdp.2006.07.007 PMid:17113721
12. PUJOL JL, SIMONY J, JOLIMOY G, et al. Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers. Br J Cancer 1996; 74: 964-970.
13. REGINA S, ROLLIN J, BLECHET C et al. Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J Thorac Oncol 2008; 3: 689-697.
14. BREMNES RM, CAMPS C, SIRERA R. Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006; 51: 143-158. doi:10.1016/j.lungcan. 2005.09.005 PMid:16360975
15. BAGLEY RG, ROULEAU C, MORGENBESSER SD et al. Pericytes from human non-small cell lung carcinomas: An attractive target for anti-angiogenic therapy. Microvascular Research 2006; 163-174.
16. FIELDING D, AGNEW J, WRIGHT D et al. DAFE autofluorescence assessment of oral cavity, larynx and bronchus in head and neck cancer patients. Photodiagnosis and Photodynamic Therapy 2006; 3: 259-265. doi:10.1016/j.pdpdt. 2006.07.004
17. TRAVIS WD, COLBY TV, SHIMOSATO Y et al. WHO/IASCL Histological classification of tumours. Histological typing of lung and pleural zumours. 3rd Edn. New York, Springer Verlag, 1999.
18. HSU SM, RAINE L, FANGER H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedure. J Histochem Cytochem 1981; 29: 577-580.
19. YANO T, TANIKAWA S, FUJIE T et al. Vacular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer 2000; 36: 601-609. doi:10.1016/S0959-8049(99)00327-5 PMid:10738124 (Pubitemid 30156845)
20. Ye B, ZHANG YX, YANG F et al. Induction of lung lesions in Wistar rats by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its inhibition by aspirin and phenethyl isocyanate. BMC Cancer 2007; 7: 90. doi:10.1186/1471-2407-7-90 PMid:17535415 PMCid:1899177 (Pubitemid 47028849)
21. ELING TE, CURTIS JF. Xenobiotic metabolism by prostaglandin H synthase. Pharmacol Ther 1992; 53: 261-273. doi:10.1016/0163-7258(92)90012-O
22. OCHIAI M, OGURI T, ISOBE T et al. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res 1999; 90: 1338-1343.
23. MARROGI AJ, TRAVIS WD, WELSH JA et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000; 6: 4739-4744. (Pubitemid 32110413)
24. RODRIGUES S, BRUYNEEL E, RODRIGUE CM et al. Cyclooxygenase 2 and carcinogenesis. Bull Cancer 2004; 91: S61-76.
25. BULLWINKEL J, BARON-LUHR B, LUDEMANN A et al. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol 2006; 206: 624-635. doi:10.1002/jcp.20494 PMid:16206250
26. KLEIN WM, HRUBAN RH, KLEIN-SZANTO JP et al. Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol 2002; 15: 441-447. doi:10.1038/modpathol.3880544 PMid:11950919
27. PICH A, CHIUSA L, FORMICONI A et al. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. Am J Surg Pathol 2001; 25: 1528-1533. doi:10.1097/00000478-200112000-00009 PMid:11717543
28. RISIO M, ROSSINI FP. Cell proliferation in colorectal adenomas containing invasive carcinoma. Anticancer Res 1993; 13: 43-47. (Pubitemid 23118193)
29. STANTON KJ, SIDNER RA, MILLER GA et al. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of pancreas. Am J Surg 2003; 186: 486-492. doi:10.1016/j.amjsurg.2003.07.002
30. BUCK AC, SCHIRMEISTER HH, GUHLMANN CA. Ki-67 immunostaining in pancreatic cancer and chronic pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 2001; 42: 721-725.
31. ISHIWATA N, JINN Y, TSUKADA Y et al. Relationship between apoptosis and immunohistochemical staining for proliferating cell nuclear antigen and Ki-67 in non-small cell lung cancer. Anticancer Res 2000; 20: 1445-1450.
32. YUAN A, YANG PC, YU CJ et al. Tumor angiogenesis correlates with histologic type and nodal metastasis in non-small cell lung carcinoma. Am J Respir Crit Care Med 1995; 152: 2157-2162.
33. ANGELETTI CA, LUCCHI M, FONTANINI G et al. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of neoadjuvant therapies in a subset of patients at high risk of recurrence. CA 1996; 78: 409-415.
34. BALUK P, HASHIZUME H, MCDONALD DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Develop 2005; 15: 102-111. doi:10.1016/j.gde.2004.12.005
35. SCHLINGEMANN RO, RIETVELD FJR, KWASPEN F et al. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulaation tissue. Am J Pathol 1991; 138: 1335-1347.
36. BREUER RH, PASIC A, SMITT EF et al. The natural course of preneoplastic lesions in bronchial epithelium. Clin Cancer Res 2005; 11: 537-543.